louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03895476: To Measure Pain Perception Following De-Epithelized Free Gingival Graft Harvesting
Official title: A Randomized Controlled Trial to Measure Pain Perception Following De-Epithelized Free Gingival Graft Harvesting
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Gingival Recession
Palate; Wound
Lead sponsor: University of Alabama at Birmingham
Sponsor class: OTHER
First posted: 2019-03-29
Enrollment: 72
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This randomized clinical comparative study will evaluate the postoperative pain following the FGG graft harvest procedure technique covered by four different methods for coverage of the palatal donor site.

Detailed description: This study will compare the application of :

* hemostatic collagen sponge
* collagen sponge sealed with abio-adhesive material
* Platelet rich fibrin
* physical barrier (stent) on the palatal donor sites with the purpose of which one of these will result in least postoperative pain after epithelialized gingival graft (EGG) harvesting.

Eligibility criteria: Inclusion Criteria:

* English speaking
* At least 18 years old- 70 years old
* Must be a patient of the UAB Dental School
* Able to read and understand informed consent document
* Patients needing soft tissue graft with teeth that have miller class I or II recession (\>=2mm) on the facial aspects
* Presence of periodontally healthy teeth at the recipient site.
* Ability of the participants to maintain good oral hygiene
* Patient not pregnant or breastfeeding
* Not taking medications known to cause gingival enlargement

Exclusion Criteria:

* Non-English speaking
* Less than 18 years old, older than 70 years old
* Smokers/tobacco users
* Patients with systemic pathologies or conditions contraindicating oral surgical procedures or adversely affecting wound healing
* Patients that have severe gingival recession (Miller class III and IV) or \< 2 mm.
* Presence of periodontal disease at the recipient site.
* Poor oral hygiene
* Patient pregnant or breastfeeding
* Taking medications known to cause gingival enlargement

Primary outcomes:
measure: Pain Assessment (0=No Pain to 10=Worst)
timeFrame: day 14
measure: Bleeding Assessment
timeFrame: day 14
Secondary outcomes:
measure: Activity Tolerance
timeFrame: day 14
measure: Amount of Swelling
timeFrame: day 14
measure: The Need for Painkiller
timeFrame: day 14
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: Unversity of Alabama at Birmingham, School of Dentistry
state: Alabama
Study officials:
References:
Clinical trial NCT07021976: A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy
Official title: A Multicentre, Randomized, Double-blind, Placebo-parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of HRS-1893 Tablets in the Treatment of Obstructive Hypertrophic Cardiomyopathy
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE3
Conditions: Obstructive Hypertrophic Cardiomyopathy
Lead sponsor: Shandong Suncadia Medicine Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2025-06-15
Enrollment: 216
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study is being conducted to evaluate the efficacy and safety of HRS-1893 for obstructive hypertrophic cardiomyopathy.


Eligibility criteria: Inclusion Criteria:

1. Age 18-85 years old, gender unlimited.
2. BMI\<35 kg/m2.
3. The diagnosis was obstructive hypertrophic cardiomyopathy.
4. Laboratory determination of echocardiography showed that Rest LVOT-G≥50 mmHg, or Rest LVOT-G≥30 mmHg and LVOT-G≥50 mmHg after Valsalva action.
5. Echocardiographic laboratory tests showed LVEF≥60%.
6. NYHA classification: Grade II - III.
7. Understand the study procedure and sign the informed consent in person, willing to strictly follow the clinical study protocol to complete the study.

Exclusion Criteria:

1. Known or suspected invasive, genetic or storage diseases (e.g. Noonan syndrome, Fabre's disease, amyloidosis) that cause cardiac hypertrophy (similar to oHCM).
2. Had a history of severe valvular heart disease.
3. Abnormal laboratory test results during screening, or any other clinically significant abnormal screening laboratory values, which are determined by the researcher to be unsuitable for inclusion.
4. Other circumstances where the researchers consider the subjects unsuitable to participate in this trial, such as physical or mental illnesses or conditions that may increase the risk of the trial, affect the subjects' compliance with the protocol, or affect the subjects' completion of the trial.

Primary outcomes:
measure: The clinical response rate of treatment with HRS-1893.
timeFrame: After 24 weeks of HRS-1893 treatment.
Secondary outcomes:
measure: The incidence of major adverse cardiac events (cardiovascular death, cardiac arrest, non-fatal stroke, non-fatal myocardial infarction, hospitalization for cardiovascular events).
timeFrame: About 29 weeks.
measure: Incidence and severity of any adverse events.
timeFrame: About 29 weeks.
measure: The change in Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score (KCCQ-CSS) from the baseline.
timeFrame: Week 12 and Week 24.
Other outcomes:
Locations:
city: Beijing
country: China
facility: Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
state: Beijing
Study officials:
References:
Clinical trial NCT03371576: Clinical Analysis of Two Toric Intraocular Lenses
Official title: Comparison of Two Toric IOL´s With Different Haptic Design: Optical Quality After 1 Year
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cataract
IOL
Keywords: toric IOL
Lead sponsor: Hospital Hietzing
Sponsor class: OTHER
First posted: 2017-12-13
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with cataract on both eyes.

Brief summary: Purpose: Comparison of two torical intraocular lenses with differents haptic design in patients with cataract.

Methods: In this prospective, randomized clinical trial 120 eyes of 60 patients underwent phacoemulsification. In patient's eyes the Tecnis torical IOL (Abbott Medical Optics) or the AT Torbi torical 709 MB IOL (Zeiss Medical AG) were randomly implanted. Three months after surgery visual acuity, rotation stability and astigmatism correction were evaluated.


Eligibility criteria: Inclusion Criteria:

* Age related cataract on both eyes
* Corneal astigmatism 1,0- 4,0 D
* Potential postoperative visus 1,0
* No other ocular pathology as cataract
* Age 18 - 80
* Written informed consent to surgery and participation in the study

Exclusion Criteria:

* Pregnancy, breastfeeding
* Amblyopy, diabetic retinopathy, uveitis or other relevant ophthalmologic diseases
* Optical media disturbances due to: corneal and vitreal opacity, PEX
* Irregular astigmatism measured with corneal topography (Visante-omni), keratoconus
* ≥ 10 degrees difference between the axis of keratometry measurement of the IOL Master and the simulated K reading of the corneal topograph (Visante-omni)
* Trauma, ocular surgery performed within 6 months
* Traumatic cataract
* Potential postoperative visus under 1,0

Primary outcomes:
measure: uncorrected visual acuity
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Mihaltz K, Lasta M, Burgmuller M, Vecsei-Marlovits PV, Weingessel B. Comparison of Two Toric IOLs with Different Haptic Design: Optical Quality after 1 Year. J Ophthalmol. 2018 Feb 11;2018:4064369. doi: 10.1155/2018/4064369. eCollection 2018.
Clinical trial NCT06292676: Emergency Home Delivery. Learning Skills for Medical Doctors and Nurses. Kirkpatrick Levels of Learning
Official title: Learning Skills for Emergency Home Delivery
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Home Birth Delivery
Keywords: home birth
emergency
skills
Lead sponsor: G. d'Annunzio University
Sponsor class: OTHER
First posted: 2024-03-05
Enrollment: 25
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: volunteers

Brief summary: Mannequin training for emergency home delivery on medical doctors and nurses

Detailed description: two groups will be exposed to frontal lecture and simulato scenario on emergency home birth. After the first training a debriefing will be done. Following a second scenario will bi performed. All participants will complete a google form questionnaire before and after addressed to understand the value of their participation.

Eligibility criteria: Inclusion Criteria:

* medical doctors and nurses

Exclusion Criteria:

* none

Primary outcomes:
measure: Kirkpatrick levels improvement
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Pescara
country: Italy
facility: Claudio Celentano
state: Italia
Study officials:
References:
Clinical trial NCT04996576: Infrazygomatic Versus Intranasal Injection Sphinopalatine Ganglion Blockade Effect on Surgical Field in FESS
Official title: Infrazygomatic Versus Intranasal Injection Approaches of Sphinopalatine Ganglion Blockade Effect on Surgical Field in Functional Endoscopic Sinus Surgeries
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Nasal Polyps
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2021-08-09
Enrollment: 35
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: This study aimed to show the effect of sphinopalatine ganglion blockade on surgical field, hemodynamics and postoperative pain in FEES operation.

Detailed description: Functional endoscopic sinus surgery (FESS) is a minimally invasive, effective surgical technique that is commonly used to treat chronic rhino sinusitis and nasal polyposis.

Intra-operative bleeding obscures the surgical view and increases the likelihood of iatrogenic complications. There are many factors that can affect the amount of bleeding experienced during surgery including both patient and surgical factors. These include severe forms of chronic sinusitis with nasal polyposis which is associated with increased vascularity, use of anticoagulant therapy, bleeding disorders, active infection, vascular tumor on the surgical site and revision surgery may affect bleeding on surgical site.

Sphenopalatine ganglion (SPG) is the main sensory innervation to the nasal mucosa.

The Sphenopalatine ganglion block (SPGB) is one of the regional anesthetic techniques that were used effectively before removal of nasal packing and in patients undergoing endoscopic sinus surgery under general anaesthesia to control bleeding or for postoperative analgesia

Eligibility criteria: Inclusion Criteria:

* Patients of ASA physical status I-II.

Exclusion Criteria:

* Patients of ASA physical status III or above.
* Patients with clinically significant cardiovascular, pulmonary or hepatic disease.
* Patients with bleeding diathesis or on anticoagulant therapy.
* Age less than 21 years.
* Mentally disabled patients.

Primary outcomes:
measure: surgical field quality
timeFrame: during the surgery
Secondary outcomes:
measure: blood pressure
timeFrame: during the surgery and after the surgery( up to 24 hours)
measure: heart rate
timeFrame: during the surgery and after the surgery( up to 24 hours)
measure: Postoperative pain
timeFrame: immediately after the surgery and 12 , 24 hours after the surgery
measure: postoperative epistaxis
timeFrame: after the surgery( up to 24 hours)
measure: postoperative infection
timeFrame: after the surgery( up to 24 hours)
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ain shams university hospitals
city: Cairo
country: Egypt
facility: Ain Shams university
Study officials:
References:
Clinical trial NCT00697476: Study of Oral Vorinostat in Combination With Topotecan in Patients With Chemosensitive Recurrent SCLC
Official title: Phase I-II Study of Oral Suberoylanilide Hydroxamic Acid (Vorinostat) in Combination With Topotecan in Patients With Chemosensitive Recurrent Small Cell Lung Cancer (SCLC)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
PHASE2
Conditions: Small Cell Lung Cancer
Keywords: second line chemotherapy
Lead sponsor: Istituto Clinico Humanitas
Sponsor class: OTHER
First posted: 2008-06-13
Enrollment: 2
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the maximum tolerated dose, the activity and the safety profile of the combination of vorinostat and topotecan in patients with recurrent small cell lung cancer


Eligibility criteria: Inclusion Criteria:

* Histologically or cytologically proven diagnosis of SCLC;
* Limited or extensive-stage disease in patients who have received a single chemotherapy regimen or combined modality (chemotherapy + chest radiotherapy) regimen and relapsed after completion of first-line chemotherapy (sensitive relapse);
* Age \>/= 18 years;
* ECOG Performance Status 0-2;
* Life expectancy of at least 12 weeks;
* Measurable lesions according to RECIST criteria;
* Adequate cardiac, hepatic, renal, and bone marrow function;
* Written informed consent.

Exclusion Criteria:

* Prior treatment with an HDAC inhibitor;
* Symptomatic and/or unstable pre-existing brain metastases;
* Superior Vena Cava Syndrome;
* Spinal cord compression;
* Severe or uncontrolled medical diseases (Hypertension, diabetes, congestive heart failure, myocardial infarction within 6 months of study, chronic renal disease, or active uncontrolled infections);
* Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ;
* Pregnant or breastfeeding women.

Primary outcomes:
measure: Maximum tolerated dose of the combination as the recommended dose for phase II trial [Phase I]; objective response rate of the combination [Phase II]; toxicity and safety profile of the combination [Phase II]
timeFrame: Limiting tolerated dose (Phase I); efficacy/toxicity after the inclusion of the last patient (Phase II)
Secondary outcomes:
measure: To assess the antitumor activity of the combination in terms of time to progression (TTP) and overall survival (OS) [Phase II]
timeFrame: After the follow up period
Other outcomes:
Locations:
city: Rozzano
country: Italy
facility: Istituto Clinico Humanitas
state: Milan
Study officials:
affiliation: Istituto Clinico Humanitas
name: Armando Santoro, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00883376: Classification of Stanford for Snore as Factor of Aggravation of the Apnea Hypopnea Index (AIH) in Patients With Obstructive Sleep Apnea Syndrome (OSAS)
Official title: Classification of Stanford for Snore as Factor of Aggravation of the AIH in Patients With OSAS.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Obstructive Sleep Apnea Syndrome
Keywords: Classification of Stanford for Snoring
OSAS
Apnea-Hipopnea Index
Lead sponsor: Irmandade da Santa Casa de Misericoridia de Limeira
Sponsor class: OTHER
First posted: 2009-04-17
Enrollment: 159
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Patients of ambulatory of Sleep Respiratory Disorders of Santa Casa de Limeira

Brief summary: Introduction: Obstructive sleep apnea syndrome (OSAS) became an important and prevalent illness in recent years. The population occidental becomes fat each time, and this symptom is associated the biggest risk for the OSAS. Snore presence is extremely associated with OSAS. Snoring is present in about 90 - 95% of the patients with OSAS.

Objectives: Evaluate the influence in the Stanford classification as predictor factor of gravity of the OSAS.

Materials and Methods: They evaluated and classified 107 patients, Classification of Mallampati, Friedman, Classification of Stanford and how much the gravity of the OSAS for the AIH.


Eligibility criteria: Inclusion Criteria:

* Not exhibiting any exclusion criteria
* Age \> 21 years

Exclusion Criteria:

* Nasal tumor
* BMI \>40
* Nasal polipose
* No acceptance of study

Primary outcomes:
measure: Stanford Classification for snoring
timeFrame: One year
Secondary outcomes:
measure: Apnea-Hyponea Index
timeFrame: one year
Other outcomes:
Locations:
city: Limeira
country: Brazil
facility: Hospital Dia
state: S
Study officials:
References:
Clinical trial NCT04616976: COVID-19 With Convalescent Plasma
Official title: Efficiency of Convalescent Plasma Therapy in Management of Critically Ill Patients With COVID-19: a Matched Case-control Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: COVID-19 Convalescent Plasma Treatment
Keywords: convalescent plasma therapy
COVID-19
mortality
Lead sponsor: Southeast University, China
Sponsor class: OTHER
First posted: 2020-11-05
Enrollment: 78
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All adult patients with COVID-19 who were admitted to ICUs of the participating hospitals between January 1 to February 29, 2020 were screened.

Brief summary: To clarify the effects of convalescent plasma therapy on SARS-CoV-2 negative conversion rate during hospital stay and 28-day mortality of severe and life-threatening COVID-19 patients.


Eligibility criteria: Inclusion Criteria:

1. \> 18 years of age;
2. laboratory-confirmed diagnosis of COVID-19;
3. respiratory failure requiring advanced respiratory support (i.e. high flow nasal cannula\[HFNC\], noninvasive mechanical ventilation \[NIV\], and invasive mechanical ventilation \[IMV\]).

Exclusion Criteria:

* no

Primary outcomes:
measure: 28-day mortality
timeFrame: 28 days
Secondary outcomes:
measure: SARS-CoV-2 negative conversion rate
timeFrame: up to 60 days
Other outcomes:
Locations:
city: Nanjing
country: China
facility: Zhongda Hospital, Southeast University
state: Jiangsu
Study officials:
References:
citation: Pan C, Chen H, Xie J, Huang Y, Yang Y, Du B, Qiu H. The Efficiency of Convalescent Plasma Therapy in the Management of Critically Ill Patients Infected With COVID-19: A Matched Cohort Study. Front Med (Lausanne). 2022 Jun 16;9:822821. doi: 10.3389/fmed.2022.822821. eCollection 2022.
Clinical trial NCT03600376: Study to Assess the Efficacy and Safety of Ryanodex as Adjuvant Treatment in Subjects With EHS
Official title: Phase 3, Multi-Center, Double-Blind, Randomized, 2-Arm, Parallel Study to Assess the Efficacy and Safety of Ryanodex (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Exertional Heat Stroke
Lead sponsor: Eagle Pharmaceuticals, Inc.
Sponsor class: INDUSTRY
First posted: 2018-07-26
Enrollment: 17
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Ryanodex (dantrolene sodium) for injectable suspension plus Standard of Care
Primary purpose: TREATMENT

Brief summary: A double-blind, parallel study of Ryanodex for the adjuvant treatment of exertional heat stroke (EHS) compared to current Standard of Care (SOC) for EHS.

Detailed description: Following triage and primary assessment in the emergency medical facility, subjects will be randomized to 1 of 2 treatment arms, SOC plus Ryanodex or SOC only. Subjects will be dosed and followed for up to 6 hours post-randomization. Current SOC is limited to body cooling and supportive measures.

Eligibility criteria: Inclusion Criteria: Core body temperature of greater than or equal to 40.0 degrees C (104 degrees F); recent history of exertional activity; GCS score less than 13; tachycardia -

Exclusion Criteria: clinical severe infection; hyperthermia secondary to another condition; endotracheal intubation;; sedative drugs administered prior to or at time of study entry; likelihood of head trauma within 6 months pre-study; positive pregnancy test; history of myocardial infection within 30 days; history of seizure disorder or epilepsy; concomitant or prior use of calcium channel blockers.

-

Primary outcomes:
measure: Cumulative Incidence of Recovery of Level of Consciousness Defined as a Glasgow Coma Scale (GCS) GCS ≥ 13 [Time Frame: 90 Minutes Post-randomization]
timeFrame: 90 minutes post-randomization
Secondary outcomes:
measure: Cumulative Incidence of Recovery of Level of Consciousness Defined as a Glasgow Coma Scale (GCS) Greater Than or Equal to 13 Over the Course of the Study [Time Frame: Study Duration]
timeFrame: Treatment duration, up to 6 hours
Other outcomes:
Locations:
city: Mecca
country: Saudi Arabia
facility: King Faisal Hospital
city: Mina
country: Saudi Arabia
facility: Mina al Jisr Hospital
city: Mina
country: Saudi Arabia
facility: Mina Al-Shari Al-Jadeed Hospital
city: Mina
country: Saudi Arabia
facility: Mina Al-Wadi Hospital
Study officials:
affiliation: Eagle Pharmaceuticals, Inc.
name: Adrian Hepner
role: STUDY_DIRECTOR
References:
citation: Fisher JD, Shah AP, Norozian F. Clinical Spectrum of Pediatric Heat Illness and Heatstroke in a North American Desert Climate. Pediatr Emerg Care. 2022 Feb 1;38(2):e891-e893. doi: 10.1097/PEC.0000000000002438.
Clinical trial NCT00962676: Diagnostic Usefulness of Interferon Gamma Release Assay for Active Tuberculosis in Immunocompromised Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Tuberculosis
Keywords: suspicious of tuberculosis
immunocompromised patients
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2009-08-20
Enrollment: 140
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Sampling method: PROBABILITY_SAMPLE
Study population: suspicious of tuberculosis, immunocompromised patients such cancer patients on chemotherapy, transplantation patients, patients with immunosuppressant

Brief summary: For diagnosis of active tuberculosis, interferon-γ release assay based mycobacterium tuberculosis specific antigen may show higher sensitivity than tuberculin skin test in immunocompromised patients. Therefore, interferon-γ release assay have a role as a rapid diagnostic adjunctive methods for active tuberculosis in immunocompromised patients.


Eligibility criteria: Inclusion Criteria:

* Patient suspicious of active tuberculosis with immunocompromised condition
* Immunocompromised condition patients with

  1. solid cancer with chemotherapy
  2. hematologic malignancy
  3. organ transplantation
  4. immunosuppressant
  5. ESRD on renal replacement therapy
  6. diabetes
  7. advanced liver cirrhosis

Exclusion Criteria:

* Patients with

  1. less than 20 years
  2. who don't agree the participation of study
  3. hypersensitivity history to tuberculin
  4. pregnancy

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Yonsei Univ.
Study officials:
References: